Articles On Alcidion Group (ASX:ALC)

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

S&P/ASX 200 had its best month of the year in July finishing up 4% to record high S&P Dow Jones Indices says large cap companies continued to lead the market in July Consumer discretionary and real estate topped July sector leaders...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

ASX healthcare shares are in the red on Tuesday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) down 0.46% and the S&P/ASX 200 Index (ASX: XJO) down 0.96% in early trading. As always, there are outliers, and these two ASX hea...

ASX and regional markets are sharply lower after Wall St tech crunch All 11 local sectors hit, InfoTech smashed hardest on -2.7pc Tissue Repair leads small caps on happy TGA approval news   The benchmark has followed sharp falls across...

Alcidion Group (ASX: ALC) has been selected as the preferred supplier for a new electronic patient record (EPR) system being implemented by North Cumbria Integrated Care NHS Foundation Trust (NCIC) in the UK. The system will provide clinici...

Immutep has received regulatory clearance from the Netherlands for its Phase I clinical trial of IMP761 Alcidion nabs $4m contract in a long-term partnership with Hume Rural Health Alliance   Immutep has clearance for Phase 1 trial Immute...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

    ASX to edge lower after Wall Street pulls back Gold and Bitcoin both touched all time highs Jerome Powell’s testimony later today US time   The ASX is poised to edge lower on Wednesday, tracking movements on Wall Street. At 8am AEDT,...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ALC)) – Alcidion Group ((LVH)) – LiveHire Check it out at https://www.fnarena.com/index.php/reporting_season/ Welcome to the FNArena Corporate Results Monitor: Subscrib...

Healius has new CEO Nove Eye reports record US sales in February Cynata says first patient has been enrolled in Phase 2 trial   Healius has a new CEO, shares rip higher Healius (ASX:HLS) jumped 14% this morning after announcing that it wo...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

World Overnight SPI Overnight 6989.00 – 1.00 – 0.01% S&P ASX 200 6977.10 – 20.30 – 0.29% S&P500 4378.38 + 12.40 0.28% Nasdaq Comp 13639.86 + 121.08 0.90% DJIA 34152.60 + 56.74 0.17% S&P500 VIX 14.81 – 0.08 – 0.54%...

World Overnight SPI Overnight 6993.00 – 11.00 – 0.16% S&P ASX 200 6997.40 + 19.20 0.28% S&P500 4365.98 + 7.64 0.18% Nasdaq Comp 13518.78 + 40.50 0.30% DJIA 34095.86 + 34.54 0.10% S&P500 VIX 15.02 + 0.11 0.74% US...

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.90% to 6899.70. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spotify....

ASX200 climbs a very laudable +0.85%  Property stocks (+1.9%) and Health Care (+1.24%) have led the gains Small caps led by Loyalty Lithium, TG6 and Tambourah Metals   The Australian sharemarket has lifted strongly on the first day of the...

The Alcidion Group Ltd (ASX: ALC) share price has returned from its trading halt and sunk deep into the red. At the time of writing, the healthcare technology company's shares are down 27% to a 52-week low of 7.1 cents. What's going on wit...

Atlas Arteria's (ASX:ALC) recent share price decline reflects the material downgrade to distributions receivable by ALX from its key French toll road assets as a result of the proposed new French tax.

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AX1)) - Accent Group ((A1M)) - AIC Mines ((AIZ)) - Air New Zealand ((ALC)) - Alcidion Group ((ALK)) - Alkane Resources ((APA)) - APA Group ((A1N)) - ARN Media ((AIA)) -...

Those investors with small-cap ASX shares in their portfolio have suffered greatly over the past couple of years. Since inflation rocketed, interest rates followed, and Russia stamped into Ukraine, money was pulled out from smaller player...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Frustration can’t begin to describe what it’s like to own certain ASX stocks. The business is excellent — winning new customers, expanding market share — but the stock price just languishes, or even plunges. Even with a long-term horizon,...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

The ASX was higher by around 2.5% in July The best sectors were Tech and Energy We look at the best and worst performing ASX stocks for the month For the month of July, most major indexes on the ASX rose by around 2.5%. Name % Change...

Alcidion Group (ALC) announces its Q4 FY23 results, showing strong growth in operating cash flow and new sales The company secures a renewal contract with existing customers and forms a strategic partnership to enhance patient outcomes...

The Alcidion Group Ltd (ASX: ALC) share price is on the move today as shareholders digest the company’s fourth-quarter performance. Shares in the healthcare software provider are 9.1% higher this morning, trading hands at 12 cents apiece....

Clinical validation study confirms efficacy of INOVIQ’s SubB2M/CA15-3 test for breast cancer Ramsay releases several announcements this week including possible sale of joint Asian venture Mach 7 expects significant cash collections in Q4...

New research identifies Alcidion Group is attaining scale and becoming profitable at an opportune time for healthcare technology demand. -Alcidion Group’s expanded offering in a time of industry demand-Proven business model is scaling and b...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Neurotech will extend its Phase 1/2 trial after ethics approval Alcidion makes further inroads into UK’s public hospitals   Neurotech to extend Phase 1/2 trial after ethics approval Paediatric neurological disorders specialist, Neurotech...

Wall Street was closed for Memorial Day, European shares were slightly down Beware of “downside correction” in the US market, expert says Rampant short-selling is putting pressure on the oil markets   Wall Street was closed for Memorial D...

It remains a nerve-wracking time for investors in small-cap ASX shares. Inflation is still flying high, interest rates are still heading up, and there is still no certainty as to whether the world will avoid a recession. But, according to...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The tech heavy Nasdaq has officially entered a bull market How long do bulls market usually last? And what will the Nasdaq rally mean for ASX tech stocks?   Well, what do you know? Far from being in a crash-landing recession after the nea...

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named as b...

A deep valuation rift has emerged between the larger established tech stocks and the loss-making minnows, with fears that many of the small ‘uns simply will run out of cash in a hostile fund raising climate. Of course the collapse of Silico...